Future Directions


Bringing advanced therapies to market faster: a role for biosimulation?

In the last 10 years, genomic and proteomic technologies have been applied to identify and develop a new generation of diabetes treatments. While these technologies have become increasingly automated, producing a deluge of potential therapeutic targets and biological insights, projections estimate that individual drug development time and cost will continue to rise and soon exceed 1 billion USD. A significant contributor to this rising cost is the large

Computer-simulated modelling in the management of diabetes

Diabetes has many complications which can take decades to develop. Scores of therapies are now available for the prevention of Type 2 diabetes, and the complications of diabete. People with diabetes vary widely in their risks and histories of diabetes-related complications. How, then, can we choose from the many treatment options which are currently on offer to people with the condition?

Pancreas and islet transplantation in the management of diabetes

The relative roles of pancreas transplantation and islet transplantation in the management of diabetes are perhaps best examined in the context of the American Diabetes Association (ADA) position statement - revised in 2003. Given the growing success of islet transplantation, it seems worthwhile to examine whether the ADA recommendations should be reconsidered.

Towards an understanding of the genetic causes of diabetes

People develop Type 1 diabetes when their immune system specifically seeks out and destroys the insulin-producing ß-cells in their pancreas. The interaction of environmental factors with a number of gene variants results in the immune disturbance which causes the condition. In this article, Tony Merriman looks at the approaches used to identify the genes which make a person susceptible to Type 1 diabetes.